- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT06375343
Optive®와 PRO-240 안과용액을 비교한 연구
안과적 및 임상적으로 건강한 지원자의 안구 표면에서 Optive®와 비교하여 PRO-240 안과 용액의 안전성과 내약성을 평가하기 위한 1상 임상 연구
This is a phase I clinical study to evaluating safety and tolerability of PRO-240 ophthalmic solution through the incidence of unexpected adverse events, as well as through changes in Best Corrected Visual Acuity (BCVA), and the incidence of stinging after its administration, compared to Optive®.
연구 개요
상세 설명
The variables to be evaluated include:
Primary (safety):
- Incidence of unexpected advere events (AE's)
Secondary:
- Changes in the ocular comfort index (OCI) score
- Changes in intraocular pressure (IOP)
- Changes in Best Corrected Visual Acuity (BCVA)
- Adherence to treatment
- Changes in tear film breakup time
- Changes in fluorescein staining
- Changes in lissamine green staining
연구 유형
등록 (추정된)
단계
- 1단계
연락처 및 위치
연구 연락처
- 이름: Alejandra Sanchez-Rios, MD
- 전화번호: 33 3001 4200
- 이메일: alejandra.sanchez@sophia.com.mx
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Having the ability to voluntarily give their signed informed consent.
- Ophthalmologically and clinically healthy subjects.
- Being able to and willing to comply with scheduled visits, treatment plan, and other study procedures.
- Age ≥18 years.
- Male or female gender.
- Women of childbearing potential who have not undergone Bilateral Tubal Occlusion (BTO [Tubal Ligation]), hysterectomy, or bilateral oophorectomy must ensure continuation (initiated ≥ 30 days prior to signing the informed consent form [ICF]) of the use of a hormonal contraceptive method or intrauterine device (IUD) during the study period.
- Best corrected visual acuity (BCVA) of 20/30 or better in both eyes.
- Corneal staining ≤ grade I on the Oxford Scale.
- Having an intraocular pressure ≥ 10 and ≤ 21 mmHg.
Exclusion Criteria:
- History of hypersensitivity to any of the components of the drugs under investigation.
- Use of ophthalmic medications from any pharmacological group.
- Use of medications by any other route of administration.
- Use of non-steroidal anti-inflammatory drugs, steroid anti-inflammatory drugs, or antibiotics by any route of administration in the last 30 days.
- History of eye surgery in the last 6 months.
- Use of contact lenses for a period less than two weeks prior to the start of the study, and during the intervention period of this study.
- In the case of women: being pregnant, breastfeeding, or planning to become pregnant within the study period.
- Having participated in any clinical research study 30 days prior to inclusion in this study.
- Having previously participated in this same study.
- History of any chronic-degenerative disease, including Diabetes Mellitus or Systemic Arterial Hypertension.
- Diagnosis of glaucoma or ocular hypertension.
- Known diagnosis of liver or heart disease.
- Presenting active inflammatory or infectious disease at the time of entry into the study.
- Presenting unresolved lesions or traumas at the time of entry into the study.
- Having been subjected to non-ophthalmological surgical procedures in the last 3 months.
- Being or having an immediate family member (e.g., spouse, parent/legal guardian, sibling, or child) who is an employee of the research site or the sponsor, and who directly participates in this study.
- Active smoking (specified as the consumption of cigarettes regardless of the amount and frequency, 4 weeks prior to study inclusion and during the intervention period of this study).
- Active alcoholism (specified as the consumption of alcoholic beverages, regardless of the amount and frequency, 72 hours prior to study inclusion and during the intervention period of this study).
Elimination Criteria:
- Withdrawal of their consent to participate in the study (informed consent form).
- Occurrence of a serious adverse event, whether related or not to the interventions, that in the opinion of the principal investigator (PI) and/or the sponsor, could affect the patient's fitness to safely continue with the study procedures.
- Non-tolerability or hypersensitivity to any of the compounds used during the tests -(fluorescein, tetracaine).
- Non-tolerability or hypersensitivity to any of the drugs under investigation.
- Adherence < 80% determined by the subject's diary and corroborated by the final weight of the research products (RP) compared to the initial weight.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 네 배로
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: PRO-240
|
-Propylene glycol 0.3%, Polyethylene glycol 400 0.5%, and Glycerin 0.2%. Ophthalmic solution. |
|
활성 비교기: Optive®
|
- Carboxymethylcellulose 0.5%, and Glycerin 0.9%. Ophthalmic solution. |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Incidence of unexpected adverse events related to the interventions
기간: Days 0: (Basal Visit), 8 (Final Visit) and 11 (Safety Call)
|
Any unfavorable medical condition affecting the subject after the administration of the investigation product, related to such intervention. |
Days 0: (Basal Visit), 8 (Final Visit) and 11 (Safety Call)
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Changes in the Ocular Comfort Index score
기간: Days: 0 (Basal Visit), and 8 (Final Visit)
|
Changes in the Ocular Comfort Index (OCI) score in between interventions, the subjects will be questioned regarding this symptoms' incidence. The OCI contains 8 items (one positive and eight negative) that focus on discomfort associated with ocular surface disorders. Each of these questions has two parts, which separately inquire about the frequency and severity of symptoms. The OCI score will be used for evaluation of tolerability through incidence and severity of dry eye symptoms in a scale from 0 to 100. Greater scores mean a worse outcome. |
Days: 0 (Basal Visit), and 8 (Final Visit)
|
|
Adherence to treatment (adherence) Adherence to treatment (adherence)
기간: Days: 8 (Final Visit)
|
Adherence will be evaluated through the treatment record in the subject's diary. |
Days: 8 (Final Visit)
|
|
Changes in Best Corrected Visual Acuity (BCVA)
기간: Days: 0 (Basal Visit) and 8 (Final Visit)
|
The BCVA will be evaluated through Snellen chart. |
Days: 0 (Basal Visit) and 8 (Final Visit)
|
|
Changes in tear film breakup time
기간: Days: 0 (Basal Visit) and 8 (Final Visit)
|
The most common method for assessing stability is with fluorescein. The precorneal layer colored with fluorescein will change to less fluorescent or non-fluorescent regions. The time from the last blink to the appearance of these regions is the tear film breakup time. |
Days: 0 (Basal Visit) and 8 (Final Visit)
|
|
Changes in intraocular pressure (IOP)
기간: Days: 0 (Basal Visit) and 8 (Final Visit)
|
Previous instillation of topical anesthetic, the IOP will be measured through a Goldmann tonometer during visits |
Days: 0 (Basal Visit) and 8 (Final Visit)
|
|
Changes in the integrity of the ocular surface (fluorescein staining)
기간: Days: 0 (Basal Visit) and 8 (Final Visit)
|
Changes in the integrity of the ocular surface using fluorescein staining and evaluated through the Oxford scale. The standard Oxford scale for fluorescein staining has the following criteria: Grade 0- Equal to or less than panel A; Grade I- Equal to or less than panel B, greater than panel A; Grade II- Equal to or less than panel C, greater than panel B; Grade III- Equal or less than panel D, greater than panel C; Grade IV- Equal or less than panel E, greater than panel D; Grade V- Greater than panel E. |
Days: 0 (Basal Visit) and 8 (Final Visit)
|
|
Changes in lissamine green staining of the conjunctival surface
기간: Days: 0 (Basal Visit) and 8 (Final Visit)
|
Direct observation with slit lamp, graded according to (changes in ocular surface staining using the Sjögren's International Collaborative Clinical Alliance [SICCA].) |
Days: 0 (Basal Visit) and 8 (Final Visit)
|
공동 작업자 및 조사자
연구 기록 날짜
연구 주요 날짜
연구 시작 (추정된)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .